These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 27989827

  • 1. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
    Ebrahimian M, Hashemi M, Maleki M, Abnous K, Hashemitabar G, Ramezani M, Haghparast A.
    Int J Pharm; 2016 Dec 30; 515(1-2):708-720. PubMed ID: 27989827
    [Abstract] [Full Text] [Related]

  • 2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B, Irache JM, Gómez S, Tsapis N, Gamazo C, Espuelas MS.
    Eur J Pharm Biopharm; 2008 Sep 30; 70(1):98-108. PubMed ID: 18501572
    [Abstract] [Full Text] [Related]

  • 3. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
    Wang Q, Tan MT, Keegan BP, Barry MA, Heffernan MJ.
    Biomaterials; 2014 Sep 30; 35(29):8385-93. PubMed ID: 24986256
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
    Wusiman A, Gu P, Liu Z, Xu S, Zhang Y, Hu Y, Liu J, Wang D, Huang X.
    Int J Nanomedicine; 2019 Sep 30; 14():3221-3234. PubMed ID: 31123399
    [Abstract] [Full Text] [Related]

  • 7. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
    San Román B, Gómez S, Irache JM, Espuelas S.
    J Pharm Pharm Sci; 2014 Jan 26; 17(4):541-53. PubMed ID: 25579433
    [Abstract] [Full Text] [Related]

  • 10. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
    Tafaghodi M, Khamesipour A, Jaafari MR.
    Parasitol Res; 2011 May 26; 108(5):1265-73. PubMed ID: 21125294
    [Abstract] [Full Text] [Related]

  • 11. The Immunoenhancement Effects of Polyethylenimine-Modified Chinese Yam Polysaccharide-Encapsulated PLGA Nanoparticles as an Adjuvant.
    Zhang Y, Gu P, Wusiman A, Xu S, Ni H, Qiu T, Liu Z, Hu Y, Liu J, Wang D.
    Int J Nanomedicine; 2020 May 26; 15():5527-5543. PubMed ID: 32848386
    [Abstract] [Full Text] [Related]

  • 12. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
    Diwan M, Elamanchili P, Cao M, Samuel J.
    Curr Drug Deliv; 2004 Oct 26; 1(4):405-12. PubMed ID: 16305402
    [Abstract] [Full Text] [Related]

  • 13. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
    Singh SM, Alkie TN, Nagy É, Kulkarni RR, Hodgins DC, Sharif S.
    Vaccine; 2016 Sep 14; 34(40):4807-13. PubMed ID: 27543454
    [Abstract] [Full Text] [Related]

  • 14. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
    Zhang XQ, Dahle CE, Weiner GJ, Salem AK.
    J Pharm Sci; 2007 Dec 14; 96(12):3283-92. PubMed ID: 17497736
    [Abstract] [Full Text] [Related]

  • 15. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H, Misato K, Aoshi T, Yamamoto Y, Kubota Y, Wu X, Kuroda E, Ishii KJ, Yamamoto H, Yoshioka Y.
    Front Immunol; 2018 Dec 14; 9():783. PubMed ID: 29720976
    [Abstract] [Full Text] [Related]

  • 16. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Ioannou XP, Gomis SM, Karvonen B, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S.
    Vaccine; 2002 Nov 22; 21(1-2):127-37. PubMed ID: 12443671
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polyethyleneimine-functionalized boron nitride nanospheres as efficient carriers for enhancing the immunostimulatory effect of CpG oligodeoxynucleotides.
    Zhang H, Feng S, Yan T, Zhi C, Gao XD, Hanagata N.
    Int J Nanomedicine; 2015 Nov 22; 10():5343-53. PubMed ID: 26346655
    [Abstract] [Full Text] [Related]

  • 19. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
    Inoue J, Yotsumoto S, Sakamoto T, Tsuchiya S, Aramaki Y.
    Pharm Res; 2005 Oct 22; 22(10):1627-33. PubMed ID: 16180119
    [Abstract] [Full Text] [Related]

  • 20. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
    Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S.
    Vaccine; 2005 Nov 16; 23(46-47):5450-6. PubMed ID: 16006019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.